Linda McCracken, PA
Physician Assistant · New Wilmington, PANPI 1780307850
Payments from drug & device makers
Across 438 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$884
- AstraZeneca$702
- Pfizer$693
- AbbVie$635
- Lundbeck LLC$597
- plus $4K from 23 others
What the payments were for
- Food & beverage$7,99597%
- Education$2213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 57 | $1,173 |
| Novo Nordisk | 50 | $884 |
| AstraZeneca | 24 | $702 |
| Pfizer | 36 | $693 |
| AbbVie | 43 | $635 |
| Lundbeck LLC | 35 | $597 |
| Otsuka America Pharmaceutical, Inc. | 27 | $560 |
| Exact Sciences | 17 | $459 |
| Astellas Pharma US Inc | 17 | $441 |
| Boehringer Ingelheim | 31 | $433 |
| Amgen | 22 | $396 |
| Lilly USA, LLC | 24 | $375 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $196 |
| Novartis | 7 | $115 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| Merck | 4 | $70 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Bayer | 3 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Tactile Systems Technology Inc | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Dexcom, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,216 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $71,566 |
| MounjaroTirzepatide | 47 | $62,935 |
| JardianceEmpagliflozin | 58 | $47,309 |
| OzempicSemaglutide | 34 | $44,626 |
| FarxigaDapagliflozin Propanediol | 30 | $40,524 |
| TradjentaLinagliptin | 12 | $17,464 |
| RexultiBrexpiprazole | 12 | $16,660 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $14,488 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,269 |
| LinzessLinaclotide | 19 | $12,935 |
| XareltoRivaroxaban | 13 | $10,291 |
| Repatha SureclickEvolocumab | 17 | $9,050 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $8,963 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,247 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $693 | $71,56669 claims |
| Boehringer IngelheimJardiance, Tradjenta | $433 | $64,77370 claims |
| Lilly USA, LLCMounjaro | $375 | $62,93547 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $702 | $55,01249 claims |
| Novo NordiskOzempic | $884 | $44,62634 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,173 | $24,64347 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $560 | $16,66012 claims |
| AbbVieLinzess, Synthroid | $635 | $13,98833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in New Wilmington
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.